Kiora Pharmaceuticals (KPRX) Competitors $2.64 -0.06 (-2.22%) Closing price 03:59 PM EasternExtended Trading$2.70 +0.06 (+2.27%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. OKUR, SNTI, MRSN, MURA, MDCX, XLO, JATT, XCUR, SCYX, and DYAIShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), Mersana Therapeutics (MRSN), Mural Oncology (MURA), Medicus Pharma (MDCX), Xilio Therapeutics (XLO), JATT Acquisition (JATT), Exicure (XCUR), SCYNEXIS (SCYX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors OnKure Therapeutics Senti Biosciences Mersana Therapeutics Mural Oncology Medicus Pharma Xilio Therapeutics JATT Acquisition Exicure SCYNEXIS Dyadic International Kiora Pharmaceuticals (NASDAQ:KPRX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has higher valuation and earnings, KPRX or OKUR? Kiora Pharmaceuticals has higher revenue and earnings than OnKure Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.57$3.60M-$2.91-0.91OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.51 Do insiders and institutionals hold more shares of KPRX or OKUR? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, KPRX or OKUR? Kiora Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Does the media prefer KPRX or OKUR? In the previous week, Kiora Pharmaceuticals had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of -0.07 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kiora Pharmaceuticals Neutral OnKure Therapeutics Very Positive Is KPRX or OKUR more profitable? Kiora Pharmaceuticals' return on equity of -47.17% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% OnKure Therapeutics N/A -60.52%-55.43% Do analysts rate KPRX or OKUR? Kiora Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 278.79%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 1,219.73%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50OnKure Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.14 SummaryOnKure Therapeutics beats Kiora Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.06M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.60%P/E Ratio-0.9123.5374.5925.92Price / Sales0.57534.79453.5485.33Price / Cash2.19169.2537.0859.91Price / Book0.315.3712.156.29Net Income$3.60M$32.95M$3.28B$270.77M7 Day Performance-1.49%1.31%0.99%3.36%1 Month Performance5.60%8.31%7.21%6.41%1 Year Performance-27.07%0.29%63.07%28.24% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.3781 of 5 stars$2.64-2.2%$10.00+278.8%-24.6%$9.06M$16.02M-0.9110Short Interest ↑OKUROnKure Therapeutics3.5837 of 5 stars$2.80+1.6%$32.33+1,056.8%N/A$37.82MN/A-0.58N/ASNTISenti Biosciences3.2416 of 5 stars$1.40-4.8%$8.50+507.1%-54.6%$36.62M$2.56M-0.164Positive NewsShort Interest ↓MRSNMersana Therapeutics3.9537 of 5 stars$7.28-0.6%$56.60+678.0%-83.1%$36.30M$40.50M-0.50150Gap DownMURAMural Oncology2.5453 of 5 stars$2.09+1.2%$12.00+475.5%-35.5%$36.11MN/A-0.24119Short Interest ↑MDCXMedicus Pharma1.7991 of 5 stars$2.02+4.1%$23.50+1,063.4%N/A$36.00MN/A-1.51N/AXLOXilio Therapeutics2.7648 of 5 stars$0.69-0.9%$3.00+332.3%-5.0%$35.97M$6.34M-0.9170JATTJATT AcquisitionN/A$2.04-3.8%N/A-41.1%$35.19MN/A0.003High Trading VolumeXCURExicure1.3785 of 5 stars$5.51-1.9%N/A+132.3%$34.78MN/A-1.4250Positive NewsGap UpSCYXSCYNEXIS1.6316 of 5 stars$0.82-1.4%N/A-15.7%$34.37M$3.75M-2.0560Positive NewsGap UpDYAIDyadic International2.5997 of 5 stars$0.93+1.3%$6.00+543.1%-20.8%$33.77M$3.49M-4.917Short Interest ↑ Related Companies and Tools Related Companies OnKure Therapeutics Competitors Senti Biosciences Competitors Mersana Therapeutics Competitors Mural Oncology Competitors Medicus Pharma Competitors Xilio Therapeutics Competitors JATT Acquisition Competitors Exicure Competitors SCYNEXIS Competitors Dyadic International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPRX Stock Alerts